Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Jesse T. Steffens"'
Autor:
Elizabeth E. Zumbrun, Carly B. Garvey, Jay B. Wells, Ginger C. Lynn, Sean Van Tongeren, Jesse T. Steffens, Kelly S. Wetzel, Laura M. Gomba, Kristan A. O’Brien, Franco D. Rossi, Xiankun Zeng, Eric D. Lee, Jo Lynne W. Raymond, Diana A. Hoffman, Alexandra N. Jay, Elizabeth S. Brown, Paul A. Kallgren, Sarah L. Norris, Jean Cantey-Kiser, Humza Kudiya, Chris Arthur, Christiana Blair, Darius Babusis, Victor C. Chu, Bali Singh, Roy Bannister, Danielle P. Porter, Tomas Cihlar, John M. Dye
Publikováno v:
Viruses, Vol 15, Iss 12, p 2335 (2023)
Marburg virus (MARV) causes severe disease and high mortality in humans. The objective of this study was to characterize disease manifestations and pathogenesis in cynomolgus macaques exposed to MARV. The results of this natural history study may be
Externí odkaz:
https://doaj.org/article/888ce560fbcf4156b170e652f06b91dc
Autor:
Karen A.O. Martins, Christopher L. Cooper, Sabrina M. Stronsky, Sarah L.W. Norris, Steven A. Kwilas, Jesse T. Steffens, Jacqueline G. Benko, Sean A. van Tongeren, Sina Bavari
Publikováno v:
EBioMedicine, Vol 3, Iss C, Pp 67-78 (2016)
Protein-based vaccines offer a safer alternative to live-attenuated or inactivated vaccines but have limited immunogenicity. The identification of adjuvants that augment immunogenicity, specifically in a manner that is durable and antigen-specific, i
Externí odkaz:
https://doaj.org/article/8f5266c8c2794d2ba9f9e84dfad01f33
Autor:
Alicia M. Moreau, Robert Jordan, Roy Bannister, Christiana Blair, Jesse T. Steffens, Nicole L. Garza, Laura Gomba, Jay Wells, Jessica M. Weidner, Danielle P. Porter, Travis K. Warren, Ginger Donnelly, Tomas Cihlar, Eric Lee, Sean A. Van Tongeren, Jeremy J. Bearss, Kelly S. Wetzel, Sina Bavari
Publikováno v:
The Journal of Infectious Diseases. 222:1894-1901
Marburg virus (MARV) is a filovirus with documented human case-fatality rates of up to 90%. Here, we evaluated the therapeutic efficacy of remdesivir (GS-5734) in nonhuman primates experimentally infected with MARV. Beginning 4 or 5 days post inocula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9017f08b19cc35fa3df2429372ac3bb9
https://doi.org/10.1093/infdis/jiaa290
https://doi.org/10.1093/infdis/jiaa290
Autor:
Kelly S. Stuthman, Jessica M. Weidner, Christopher D. Kane, Nicole L. Garza, Jesse T. Steffens, Ginger Donnelly, Danielle P. Porter, Roy Bannister, Xiankun Zeng, Sina Bavari, Jay Wells, Sarah L. Norris, Patrick L. Iversen, Travis K. Warren, Laura Gomba, Sean A. Van Tongeren, Tomas Cihlar
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports
Scientific Reports
Efficacious therapeutics for Ebola virus disease are in great demand. Ebola virus infections mediated by mucosal exposure, and aerosolization in particular, present a novel challenge due to nontypical massive early infection of respiratory lymphoid t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::403549e314fcaa2ffe4b93d6053217b2
https://doi.org/10.1038/s41598-021-98971-0
https://doi.org/10.1038/s41598-021-98971-0
Autor:
Sean A. Van Tongeren, Sabrina M. Stronsky, Jesse T. Steffens, Yao Xu, Christopher L. Cooper, James J. Moon, Yuchen Fan, Amanda L. Erwin
Publikováno v:
ACS Nano. 13:11087-11096
Recent outbreaks of emerging infectious diseases, such as Ebola virus disease (EVD), highlight the urgent need to develop effective countermeasures, including prophylactic vaccines. Subunit proteins derived from pathogens provide a safe source of ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::246dca33fa89ae703d0e1f59b77d4e7f
https://doi.org/10.1021/acsnano.9b03660
https://doi.org/10.1021/acsnano.9b03660
Autor:
Christopher L. Cooper, Laura C. Kalinyak, Sabrina M. Stronsky, Joseph Bazzill, Jesse T. Steffens, James J. Moon, Lukasz J. Ochyl, Sean A. Van Tongeren
Publikováno v:
Nanomedicine
The recent outbreaks of Ebolavirus (EBOV) in West Africa underscore the urgent need to develop an effective EBOV vaccine. Here, we report the development of synthetic nanoparticles as a safe and highly immunogenic platform for vaccination against EBO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b35b2f64933805b956c6b13c93f04de
https://doi.org/10.1016/j.nano.2018.11.005
https://doi.org/10.1016/j.nano.2018.11.005
Autor:
James J Sola, Perry D Wiseman, Joseph Henry, Jay Wells, Joshua L. Moore, Christopher W. Schellhase, Xiankun Zeng, Jeremy J Bearss, Kelly S. Stuthman, Luis A. Lugo-Roman, Jennifer Kalapaca, Darrel Wetzel, Elliot Ramos-Rivera, Annie Madar, William D. Pratt, Veronica Soloveva, Ginger Donnelly, Lydia G Downey, Tami Unangst, Nicole L. Garza, Adele Miller, Jesse T. Steffens, Janice A. Williams, Anthony P. Cardile, Mark G. Kortepeter, Paul W Blair, Isaac L Downs, Mark A. Chappell, Ronald B. Reisler, Franco Rossi, Shannon T Marko, Christian Hofer, Jimmy O. Fiallos, Sean A. Vantongeren, Eugene Blue, Cristian Madar, Karen A. Martins, Sina Bavari
Publikováno v:
J Infect Dis
BackgroundEbola virus disease (EVD) supportive care strategies are largely guided by retrospective observational research. This study investigated the effect of EVD supportive care algorithms on duration of survival in a controlled nonhuman primate (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c7edbda2a606ce080f14190d836c477
https://pubmed.ncbi.nlm.nih.gov/33367826
https://pubmed.ncbi.nlm.nih.gov/33367826
Autor:
Christiana Blair, Roy Bannister, Sina Bavari, Jacqueline Tarrant, Matthew C. Reed, Ginger Donnelly, Joshua D. Shamblin, Adrienne E. Kimmel, Travis K. Warren, Laura Gomba, Kelly S. Wetzel, Sean A. Van Tongeren, Jesse T. Steffens, Jessica M. Weidner, Tomas Cihlar, Nicole Lackemeyer, Franco Rossi, Jay Wells, Elizabeth E. Zumbrun, Bali Singh, Danielle P. Porter, Holly A. Bloomfield, Eric Lee, Carly Garvey, Jo Lynne Raymond
Publikováno v:
Viruses, Vol 12, Iss 1, p 92 (2020)
Viruses
Volume 12
Issue 1
Viruses
Volume 12
Issue 1
Recent Ebola virus (EBOV) outbreaks in West Africa and the Democratic Republic of the Congo have highlighted the urgent need for approval of medical countermeasures for treatment and prevention of EBOV disease (EVD). Until recently, when successes we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e339f7f54ceadd5b52cf21989fadd700
https://www.mdpi.com/1999-4915/12/1/92
https://www.mdpi.com/1999-4915/12/1/92
Autor:
Christopher L. Cooper, Karen A. Martins, Sean A. Van Tongeren, Sabrina M. Stronsky, Sina Bavari, David Langan, Jesse T. Steffens
Publikováno v:
Emerging Microbes & Infections. 6:1-9
Humoral responses are essential for the protective efficacy of most Ebola virus (EBOV) candidate vaccines; however, the in vivo development of protective anti-EBOV B-cell responses is poorly defined. Here, by using the virus-like particle (VLP) as a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::991af040db151d319bc3c834af842b22
https://doi.org/10.1038/emi.2017.31
https://doi.org/10.1038/emi.2017.31
Autor:
Karen A. Martins, Sean A. Van Tongeren, Sina Bavari, Sabrina M. Stronsky, Christopher L. Cooper, Jesse T. Steffens, Nikolai Petrovsky
Publikováno v:
Vaccine
The establishment of correlates of protection is particularly relevant in the context of rare, highly lethal pathogens. We previously demonstrated that an Ebola glycoprotein virus-like particle (VLP) vaccine, when given as two intramuscular doses, co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52d9f4da6b06dab20f8f0c8d7e70124a
https://pubmed.ncbi.nlm.nih.gov/32418798
https://pubmed.ncbi.nlm.nih.gov/32418798